Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Chemotherapy and Flora in Gastric and Colon Cancer
NCT04198051Unknown
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Dec 2019
- Primary completion
- Dec 2020
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of oxaliplatin, tegafur, capecitabine, fluorouracil and folinic acid in gastric cancer (GC) and colon cancer, sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoint: Change of diversity of intestinal flora in faeces at 6 months. Status: unknown.
02
Drugs
oxaliplatintegafurcapecitabinefluorouracilfolinic acid
03
Conditions
gastric cancer (GC)colon cancer
Beyond the preview
Go deeper on NCT04198051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04198051.